SANUWAVE Health announced that the company has signed a $1 million equipment financing lease agreement with NFS Leasing, Inc.  This agreement will enable SANUWAVE to begin placing the dermaPACE® System in the hands of clinicians and wound care centers in the United States to utilize in the treatment of diabetic foot ulcers, a billion dollar market.

“The agreement with NFS is a crucial announcement for the company as we execute our plan for a successful rollout in the massive U.S. diabetic foot ulcer (DFU) market.  This allows us to access capital to place devices which in turn will drive procedures and ultimately revenue,” stated Kevin A. Richardson II, Chief Executive Officer of SANUWAVE.  “We have a well developed plan in place to roll out dermaPACE methodically throughout 2018.  We are very excited to have this line in place which allows us to launch our rapid revenue growth,” concluded Mr. Richardson.

The Company has had overwhelming inbound information calls and support from the wound care community since the announcement of its FDA clearance.  The company anticipates the first draw on this line later in February with initial delivery shortly thereafter.

“We have been following SANUWAVE’s progress for a while and began discussions about doing business together prior to their good news from the FDA.  We are glad to be providing capital for a business model that will help heal a massive medical problem involving diabetic foot ulcers.  The Company has developed a great go to market strategy and we are looking forward to a successful strategic relationship,” stated David DePamphilis, Chief Operating Officer of NFS Leasing, Inc.